BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

PALO ALTO, Calif., Jan. 30, 2018 -- (Healthcare Sales & Marketing Network) -- BridgeBio Pharma today announced that it is has licensed infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, from Novartis. In a... Biopharmaceuticals, Oncology, Licensing BridgeBio Pharma, QED Therapeutics, infigratinib, Novartis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news